Navigation Links
ARIUS announces fourth quarter and year-end fiscal 2007 financial results
Date:1/29/2008

s non-executive Chair

of the Board of Directors.

Financial Results:

All amounts are in Canadian dollars unless otherwise indicated.

For the year ended November 30, 2007, the Company recorded a net loss of $11,057,039 compared to a net loss of $6,444,189 for the year ended November 30, 2006. The increase in net loss was the result of higher research and development, general administrative and foreign exchange expenses and lower revenues, partially offset by lower interest expense and the absence of a loss on extinguishment of debt. For the three-month period ended November 30, 2007, the Company recorded a net loss of $2,952,338 compared to a net loss of $3,623,727 for the three-month period ended November 30, 2006. This decrease in net loss for the three-month period is primarily the result of lower research and development, general and administrative and interest expenses and the 2006 one time loss on extinguishment of debt of $782,143 relating to the repayment of the convertible bridge loan, partially offset by higher foreign exchange losses and income tax expense.

Revenue decreased to $1,144,094 for the year ended November 30, 2007, compared to $2,847,761 for the year ended November 30, 2006. The decrease during the year ended November 30, 2007, was primarily the result of the recognition of licensing fee revenue from Genentech in the fiscal 2006 period and a decrease in financial contributions from the National Research Council's Industrial Research Assistance Program, partially offset by the recognition of product and research contract revenue from the Takeda collaboration and the recognition of unearned revenue for PDL BioPharma Inc. in the fiscal 2007 period. For the three-month period ended November 30, 2007, the Company's revenue increased to $298,120 compared to $179,751 for the three-month period ended November 30, 2006. The increase was primarily the result of the recognition of product and research contract revenue fr
'/>"/>

SOURCE ARIUS Research Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13

Related biology technology :

1. Arius completes Pre-IND Meeting with FDA for Lead CD44 Cancer Stem Cell Program
2. ARIUS to Hold Fourth Quarter and Year End 2007 Conference Call
3. ARIUS announces manufacturing agreement with Avid Bioservices for CD44 Cancer Stem Cell antibody
4. ARIUS to present at BioNorth Biotechnology and Life Sciences Conference
5. Arius announces new findings in Trop-2 and CD59 CANCER antibody programs
6. ARIUS announces cancer stem cell antibody program successfully completes first toxicology study
7. ARIUS to present at Chinese Global Financial Forum
8. Arius highlighted at AACR-NCI-EORTC 2007 International Cancer Conference
9. ARIUS Announces Third Quarter Fiscal 2007 Financial Results
10. Arius Features Preclinical Data on Antibody Candidates at Two Conferences
11. China Bionanometer Industries Corporation Announces Record Second Quarter 2007 Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/11/2014)... Cayenne Medical, Inc., a privately held ... tissue reconstruction segment, announced the worldwide launch of ... the shoulder and extremities. The SureLock System provides ... method. The unique delivery eliminates manual tensioning that ... anchor displacement (also commonly know as anchor “creep”). ...
(Date:7/10/2014)... (PRWEB) July 10, 2014 Understanding the ... channel-expressing cell lines, and the gap that currently exists ... that expand its industry-leading portfolio of validated ion channel ... ion channel-expressing cell lines, as ion channels control many ... control this activity creates the potential to treat a ...
(Date:7/10/2014)... Los Angeles, CA (PRWEB) July 10, 2014 ... Analytical and Bioanalytical techniques during 18-20 August, 2014 at ... to critically review the recent developments in Analytical & ... across the globe. , Speaking on this occasion, Dr. ... that Analytica Acta conference is a remarkable one ...
(Date:7/10/2014)... July 10, 2014 On July ... Medvedev , presented Russia,s first ... . The Company is developing a unique project called ... BIOCAD develops a number of innovative drugs based on ... The ceremony took place at the International Exhibition "Innoprom ...
Breaking Biology Technology:Cayenne Medical Launches SureLock™ All-Suture Anchor System for Shoulder and Extremity Surgery 2Cayenne Medical Launches SureLock™ All-Suture Anchor System for Shoulder and Extremity Surgery 3Leader in Ion Channel Research Announces Newly Validated and Re-Engineered Cells 2Leader in Ion Channel Research Announces Newly Validated and Re-Engineered Cells 3A Critical Review of Analytical Techniques for Improved Living Standards 2A Critical Review of Analytical Techniques for Improved Living Standards 3A Critical Review of Analytical Techniques for Improved Living Standards 4Dmitry Medvedev Presented BIOCAD the First National "Industry" Award 2
... a bioMerieux company that develops innovative oncology diagnostic tests ... from a clinical study evaluating the company,s Breast Cancer ... the study were presented at the 33rd Annual CTRC-AACR ... The company also announced that the Breast Cancer Index ...
... 2010 Pfizer Inc. (NYSE: PFE ) ... it is voluntarily withdrawing Thelin® (sitaxentan) for the treatment ... is approved (the European Union, Canada and Australia).  In ... (Logo: http://photos.prnewswire.com/prnh/20100416/PFIZERLOGO) Pfizer,s decision ...
... (Dec. 9, 2010) -- Nanotechnologists, marine biologists and signal-processing ... Woods Hole, Mass., and other U.S. universities have won ... Research to unlock the secrets of nature,s best camouflage ... emulate some of the elegant skin colors and patterns ...
Cached Biology Technology:bioTheranostics' Breast Cancer Index(SM) Predicts Risk for Late Recurrence in Early Stage ER-Positive Breast Cancer Patients 2bioTheranostics' Breast Cancer Index(SM) Predicts Risk for Late Recurrence in Early Stage ER-Positive Breast Cancer Patients 3Pfizer Stops Clinical Trials of Thelin® and Initiates Voluntary Product Withdrawal in the Interest of Patient Safety 2Pfizer Stops Clinical Trials of Thelin® and Initiates Voluntary Product Withdrawal in the Interest of Patient Safety 3Nano squid skin: DOD awards $6M for metamaterials research 2Nano squid skin: DOD awards $6M for metamaterials research 3
(Date:7/11/2014)... 2014 Researchers have pioneered a revolutionary new ... technology, called Virtual Finger, allows scientists to move ... and synapses using the flat surface of their ... imaging studies orders of magnitude more efficient, saving ... across many areas of experimental biology. The software ...
(Date:7/11/2014)... type 1 can inhibit voltage-gated calcium channel, ... release. However, some scholars demonstrated that cannabinoid ... influx and increase neurotransmitter release. Dr. Yi ... to Tongji Medical College, Huazhong University of ... voltage-clamp and calcium imaging in cultured trigeminal ...
(Date:7/10/2014)... , June 27, 2014  The American Academy ... Institute of Standards and Technology (NIST) and the ... academic research and forensic science expert members to ... is an element of the NIST,s Organization of ... among the first appointments made to the new ...
Breaking Biology News(10 mins):Virtual finger enables scientists to navigate and analyze complex 3D images 2Ten Members of the American Academy of Forensic Sciences Appointed to Forensic Science Standards Board (FSSB) 2Ten Members of the American Academy of Forensic Sciences Appointed to Forensic Science Standards Board (FSSB) 3
... Ore. -- New research has found that if you want ... or other cruciferous vegetables, you need to eat the real ... absorbed and of far less value if taken as a ... Pauling Institute at Oregon State University, is one of the ...
... has awarded UC Santa Barbara up to $15 million ... shape the future of technology in areas that will ... educate future scientists and engineers and advance the discovery ... novel polymers to next-generation microelectronics. The pioneering institute ...
... them, and although they could be effective in theory, antivirulence ... to be published in the online journal mBio ... to fight infection while avoiding the pitfalls of drug resistance. ... growth of pathogens, but antivirulence drugs prevent disease by ...
Cached Biology News:Health benefits of broccoli require the whole food, not supplements 2Health benefits of broccoli require the whole food, not supplements 3UCSB awarded $15 million by Dow to establish collaborative institute for materials research and education 2UCSB awarded $15 million by Dow to establish collaborative institute for materials research and education 3Can antivirulence drugs stop infections without causing resistance? 2
Request Info...
... Enzyme concentration - 5 units/µL ,• High ... yields ,• Leaves an 'A' overhang ... polymerase which exhibits very high activity in ... To ensure the quality of the enzyme, ...
... 5 units/µL ,• High specific activity and ... an 'A' overhang ,• Processes ... high activity in primer extension and other ... of the enzyme, each lot has been ...
... Gold® DNA Polymerase is a chemically modified ... chemical moiety is attached to the enzyme, ... the first ramp of thermal cycling (when ... temperatures), the enzyme is inactive. The result ...
Biology Products: